HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025

Reuters

2025/09/26

HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025

HBM Holdings Ltd. reported its interim results for the six months ended 30 June 2025. Revenue for the period was US$101.3 million, compared to US$23.7 million in the same period of 2024. Profit for the period reached US$73.0 million, up from US$1.4 million in the prior-year period. Diluted earnings per share were US$0.09, compared to US$0.00 in the previous year. Cash and cash equivalents stood at US$320.7 million as of 30 June 2025, compared to US$166.8 million at 31 December 2024. Total assets increased to US$380.5 million from US$215.0 million at year-end 2024, while total equity rose to US$283.6 million from US$124.1 million. During the reporting period, HBM Holdings entered a global strategic collaboration with AstraZeneca to develop multi-specific antibodies in immunology, oncology, and other areas. As part of the agreement, AstraZeneca acquired 9.15% of newly issued shares of Harbour BioMed for US$105 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2570003399"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570003399\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570003399?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 16:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570003399","market":"nz","top_or_hot":-1,"title":"HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HBM Holdings Ltd. reported its interim results for the six months ended 30 June 2025. Revenue for the period was US$101.3 million, compared to US$23.7 million in the same period of 2024. Profit for the period reached US$73.0 million, up from US$1.4 million in the prior-year period. Diluted earnings per share were US$0.09, compared to US$0.00 in the previous year. Cash and cash equivalents stood at US$320.7 million as of 30 June 2025, compared to US$166.8 million at 31 December 2024. Total assets increased to US$380.5 million from US$215.0 million at year-end 2024, while total equity rose to US$283.6 million from US$124.1 million. During the reporting period, HBM Holdings entered a global strategic collaboration with AstraZeneca to develop multi-specific antibodies in immunology, oncology, and other areas. As part of the agreement, AstraZeneca acquired 9.15% of newly issued shares of Harbour BioMed for US$105 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-26 16:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HBM Holdings Ltd. reported its interim results for the six months ended 30 June 2025. Revenue for the period was US$101.3 million, compared to US$23.7 million in the same period of 2024. Profit for the period reached US$73.0 million, up from US$1.4 million in the prior-year period. Diluted earnings per share were US$0.09, compared to US$0.00 in the previous year. Cash and cash equivalents stood at US$320.7 million as of 30 June 2025, compared to US$166.8 million at 31 December 2024. Total assets increased to US$380.5 million from US$215.0 million at year-end 2024, while total equity rose to US$283.6 million from US$124.1 million. During the reporting period, HBM Holdings entered a global strategic collaboration with AstraZeneca to develop multi-specific antibodies in immunology, oncology, and other areas. As part of the agreement, AstraZeneca acquired 9.15% of newly issued shares of Harbour BioMed for US$105 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034235188.USD","symbol_name":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDLSx6x2:1","article_id":"2570003399","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570003399","pubTimestamp":1758875853,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","BK1574":"生物医药B类股","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0345777147.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) ACC","AZN.UK":"阿斯利康制药","BK1583":"高瓴概念","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","02142":"和铂医药-B","LU0963555726.SGD":"Blackrock European Fund A2 SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0526926950.USD":"贝莱德欧洲基金","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK5011":"制药","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","03165":"华夏欧优股对冲","LU0047473722.EUR":"HSBC GIF EUROPE VALUE \"PD\" (EUR) INC","LU0957799991.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"ZUH\" (USDHDG) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU1880407132.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) ACC","LU0784385170.HKD":"BGF GLOBAL MULTI ASSET INCOME \"A6\" (HKDHGD) INC","LU0823399737.USD":"BNP PARIBAS EUROPE EQUITY \"C\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","BK1161":"生物科技","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC"},"translate_title":"HBM Holdings Ltd.中期业绩：营收飙升至1.013亿美元，净利润跃升至7300万美元，2025年上半年基本每股收益为0.09美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9,"AZN.UK":0.9,"03165":0.6},"content_text":"HBM Holdings Ltd. Interim Results: Revenue Surges to US$101.3 Million, Net Profit Jumps to US$73.0 Million, Basic EPS at US$0.09 for First Half of 2025\n    \n\n        HBM Holdings Ltd. reported its interim results for the six months ended 30 June 2025. Revenue for the period was US$101.3 million, compared to US$23.7 million in the same period of 2024. Profit for the period reached US$73.0 million, up from US$1.4 million in the prior-year period. Diluted earnings per share were US$0.09, compared to US$0.00 in the previous year. Cash and cash equivalents stood at US$320.7 million as of 30 June 2025, compared to US$166.8 million at 31 December 2024. Total assets increased to US$380.5 million from US$215.0 million at year-end 2024, while total equity rose to US$283.6 million from US$124.1 million. During the reporting period, HBM Holdings entered a global strategic collaboration with AstraZeneca to develop multi-specific antibodies in immunology, oncology, and other areas. As part of the agreement, AstraZeneca acquired 9.15% of newly issued shares of Harbour BioMed for US$105 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}